Curient rises 8% on ADC co-commercialization deal with Lonza [Why Bio]
Predicted impact: Medium· Actual: −4.5% vs sector, volume 1.8× normal (5 trading days)
Licensing and co-commercialization deal with Lonza; value undisclosed but shares rose 8%.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.